•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.atai Life Sciences announces pricing of $55M public offering of shares
atai Life Sciences Announces Pricing of Public Offering of Common Shares
atai Life Sciences unveils $55M public offering to advance mental health treatments
atai Life Sciences Announces Proposed Public Offering of Common Shares
atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial - ICYMI
atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe
atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts
atai Life Sciences unveils positive results from Beckley Psytech's alcohol use disorder trial
Spravato sales surged highlights commercial viability of psychedelics, analysts believe
atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts
atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Psychedelic Stock Deep Dive: Atai Life Sciences
atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.